-
1
-
-
84872669358
-
Résumé des caractéristiques du produit lacosamide
-
Résumé des caractéristiques du produit lacosamide. Éditions du Vidal 2010
-
(2010)
Éditions du Vidal
-
-
-
2
-
-
77952211058
-
Efficacy and safety of lacosamide in painful diabetic neuropathy
-
Ziegler D, Hidvégi T, Gurieva I, et al. Efficacy and safety of lacosamide in painful diabetic neuropathy. Diabetes Care 2010; 33: 839-41
-
(2010)
Diabetes Care
, vol.33
, pp. 839-841
-
-
Ziegler, D.1
Hidvégi, T.2
Gurieva, I.3
-
4
-
-
78650789188
-
Intravenous lacosamide for treatment of status epilepticus
-
Kellinghaus C, Berning S, Immisch I, et al. Intravenous lacosamide for treatment of status epilepticus. Acta Neurol Scand 2011; 123: 137-41
-
(2011)
Acta Neurol Scand
, vol.123
, pp. 137-141
-
-
Kellinghaus, C.1
Berning, S.2
Immisch, I.3
-
5
-
-
59749093137
-
Intravenous lacosamide as successful treatment for nonconvulsive status epilepticus after failure of first-line therapy
-
Kellinghaus C, Berning S, Besselmann M. Intravenous lacosamide as successful treatment for nonconvulsive status epilepticus after failure of first-line therapy. Epilepsy Behav 2009; 14: 429-31
-
(2009)
Epilepsy Behav
, vol.14
, pp. 429-431
-
-
Kellinghaus, C.1
Berning, S.2
Besselmann, M.3
-
6
-
-
84859322846
-
Adjunctive treatment with lacosamide: An option for generalized epilepsy?
-
Arnold S, Beige A. Adjunctive treatment with lacosamide: an option for generalized epilepsy? Epilepsia 2010; 51(suppl 4): 118
-
(2010)
Epilepsia
, vol.51
, Issue.SUPPL. 4
, pp. 118
-
-
Arnold, S.1
Beige, A.2
-
7
-
-
34247855780
-
Lacosamide: A review of preclinical properties
-
DOI 10.1111/j.1527-3458.2007.00001.x
-
Beyreuther BK, Freitag J, Heers C, et al. Lacosamide: a review of preclinical properties. CNS Drug Rev 2007; 13: 21-42 (Pubitemid 46697839)
-
(2007)
CNS Drug Reviews
, vol.13
, Issue.1
, pp. 21-42
-
-
Beyreuther, B.K.1
Freitag, J.2
Heers, C.3
Krebsfanger, N.4
Scharfenecker, U.5
Stohr, T.6
-
8
-
-
77952665352
-
Lacosamide as treatment of epileptic seizures -Cost utility results for Sweden
-
Bolin K, Berggren F, Forsgren L. Lacosamide as treatment of epileptic seizures -cost utility results for Sweden. Acta Neurol Scand 2010; 121: 406-12
-
(2010)
Acta Neurol Scand
, vol.121
, pp. 406-412
-
-
Bolin, K.1
Berggren, F.2
Forsgren, L.3
-
9
-
-
33846234734
-
Lacosamide
-
DOI 10.1016/j.nurt.2006.10.002, PII S1933721306001759, New Antiepileptic Drugs: Discovery, Development, and Update
-
Doty P, Rudd GD, Stoehr T, et al. Lacosamide. Neurotherapeutics 2007; 4: 145-8 (Pubitemid 46107317)
-
(2007)
Neurotherapeutics
, vol.4
, Issue.1
, pp. 145-148
-
-
Doty, P.1
Rudd, G.D.2
Stoehr, T.3
Thomas, D.4
-
10
-
-
58149215498
-
Lacosamide: Pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures
-
Beydoun A, D'Souza J, Hebert D, et al. Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures. Expert Rev Neurother 2009; 9: 33-42
-
(2009)
Expert Rev Neurother
, vol.9
, pp. 33-42
-
-
Beydoun, A.1
D'souza, J.2
Hebert, D.3
-
11
-
-
40849086321
-
Lacosamide: An investigational drug for adjunctive treatment of partial-onset seizures
-
DOI 10.1358/dot.2008.44.1.1178468
-
Ben-Menachem E. Lacosamide: an investigational drug for adjunctive treatment of partial-onset seizures. Drugs Today (Barc) 2008; 44: 35-40 (Pubitemid 351397411)
-
(2008)
Drugs of Today
, vol.44
, Issue.1
, pp. 35-40
-
-
Ben-Menachem, E.1
-
12
-
-
63449105974
-
Lacosamide: In partial-onset seizures
-
Cross SA, Curran MP. Lacosamide: in partial-onset seizures. Drugs 2009; 69: 449-59
-
(2009)
Drugs
, vol.69
, pp. 449-459
-
-
Cross, S.A.1
Curran, M.P.2
-
13
-
-
77249137280
-
Clinical perspectives on lacosamide
-
Halford JJ, Lapointe M. Clinical perspectives on lacosamide. Epilepsy Curr 2009; 9: 1-9
-
(2009)
Epilepsy Curr
, vol.9
, pp. 1-9
-
-
Halford, J.J.1
Lapointe, M.2
-
14
-
-
77949469954
-
Lacosamide as treatment for partial epilepsy: Mechanisms of action, pharmacology, effects, and safety
-
Kellinghaus C. Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety. Ther Clin Risk Manag 2009; 5: 757-66
-
(2009)
Ther Clin Risk Manag
, vol.5
, pp. 757-766
-
-
Kellinghaus, C.1
-
15
-
-
77952727105
-
Lacosamide: New adjunctive treatment option for partial-onset seizures
-
Chung SS. Lacosamide: new adjunctive treatment option for partial-onset seizures. Expert Opin Pharmacother 2010; 11: 1595-602
-
(2010)
Expert Opin Pharmacother
, vol.11
, pp. 1595-1602
-
-
Chung, S.S.1
-
16
-
-
11144232600
-
Basic clinical pharmacologic investigations of the new antiepileptic drug SPM 927
-
Horstmann R, Bonn R, Cawello W, et al. Basic clinical pharmacologic investigations of the new antiepileptic drug SPM 927. Epilepsia 2002; 43(Suppl 7): 170
-
(2002)
Epilepsia
, vol.43
, Issue.SUPPL. 7
, pp. 170
-
-
Horstmann, R.1
Bonn, R.2
Cawello, W.3
-
17
-
-
33846242456
-
Food does not affect the pharmacokinetics of SPM 927
-
Cawello W, Kropeit D, Schiltmeyer B, et al. Food does not affect the pharmacokinetics of SPM 927. Epilepsia 2004; 45(Suppl 7): 307
-
(2004)
Epilepsia
, vol.45
, Issue.SUPPL. 7
, pp. 307
-
-
Cawello, W.1
Kropeit, D.2
Schiltmeyer, B.3
-
18
-
-
84872665828
-
Lacosamide has low potential for drug-drug interaction
-
Thomas D, Scharfenecker U, Nickel B, et al. Lacosamide has low potential for drug-drug interaction. Epilepsia 2009; 50(Suppl 4): 110
-
(2009)
Epilepsia
, vol.50
, Issue.SUPPL. 4
, pp. 110
-
-
Thomas, D.1
Scharfenecker, U.2
Nickel, B.3
-
19
-
-
33846193132
-
Bioequivalence of short-time infusions compared to oral administration of SPM 927
-
Kropeit D, Schiltmeyer B, Cawello W, et al. Bioequivalence of short-time infusions compared to oral administration of SPM 927. Epilepsia 2004; 45(Suppl 7): 123
-
(2004)
Epilepsia
, vol.45
, Issue.SUPPL. 7
, pp. 123
-
-
Kropeit, D.1
Schiltmeyer, B.2
Cawello, W.3
-
20
-
-
39749167069
-
Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures
-
DOI 10.1111/j.1528-1167.2007.01317.x
-
Biton V, Rosenfeld WE, Whitesides J, et al. Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia 2008; 49: 418-24 (Pubitemid 351294527)
-
(2008)
Epilepsia
, vol.49
, Issue.3
, pp. 418-424
-
-
Biton, V.1
Rosenfeld, W.E.2
Whitesides, J.3
Fountain, N.B.4
Vaiciene, N.5
Rudd, G.D.6
-
21
-
-
34447344551
-
Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures
-
DOI 10.1111/j.1528-1167.2007.01188.x
-
Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007; 48: 1308-17 (Pubitemid 47063096)
-
(2007)
Epilepsia
, vol.48
, Issue.7
, pp. 1308-1317
-
-
Ben-Menachem, E.1
Biton, V.2
Jatuzis, D.3
Abou-Khalil, B.4
Doty, P.5
Rudd, G.D.6
-
22
-
-
61849088333
-
Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial
-
Halász P, Kälviäinen R, Mazurkiewicz-Beldziñska M, et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 2009; 50: 443-53
-
(2009)
Epilepsia
, vol.50
, pp. 443-453
-
-
Halász, P.1
Kälviäinen, R.2
Mazurkiewicz-Beldziñska, M.3
-
23
-
-
77953033494
-
Lacosamide as adjunctive therapy for partial-onset seizures: A randomized controlled trial
-
Chung S, Sperling MR, Biton V, et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 2009; 50: 958-67
-
(2009)
Epilepsia
, vol.50
, pp. 958-967
-
-
Chung, S.1
Sperling, M.R.2
Biton, V.3
-
24
-
-
84864837937
-
Clinical experience with lacosamide in difficullt to treat, drug resistant patients
-
Meencke HJ, Dehnicke C, Bartels S. Clinical experience with lacosamide in difficullt to treat, drug resistant patients. Epilepsia 2009; 50(suppl 11): 250
-
(2009)
Epilepsia
, vol.50
, Issue.SUPPL. 11
, pp. 250
-
-
Meencke, H.J.1
Dehnicke, C.2
Bartels, S.3
-
25
-
-
79954500459
-
The safety and tolerability of lacosamide in randomized, double-blind, placebo-controlled phase II/III clinical trials
-
Gil-Nagel A, Biton V, Fountain N, et al. The safety and tolerability of lacosamide in randomized, double-blind, placebo-controlled phase II/III clinical trials. Epilepsia 2009; 50(Suppl 10): 110
-
(2009)
Epilepsia
, vol.50
, Issue.SUPPL. 10
, pp. 110
-
-
Gil-Nagel, A.1
Biton, V.2
Fountain, N.3
-
26
-
-
84872673260
-
Fluctuations of lacosamide serum concentrations and relation to tolerability -First clinical experience
-
Scaparra M, Sattler A, Brandt N, et al. Fluctuations of lacosamide serum concentrations and relation to tolerability -First clinical experience. Epilepsia 2009; 50(Suppl 6): 48
-
(2009)
Epilepsia
, vol.50
, Issue.SUPPL. 6
, pp. 48
-
-
Scaparra, M.1
Sattler, A.2
Brandt, N.3
-
27
-
-
33846244930
-
Pharmacokinetics of the new antiepileptic drugs SPM 927 in human subjects with different age and gender
-
Schiltmeyer B, Cawello W, Kropeit D, et al. Pharmacokinetics of the new antiepileptic drugs SPM 927 in human subjects with different age and gender. Epilepsia 2004; 45(Suppl 7): 313
-
(2004)
Epilepsia
, vol.45
, Issue.SUPPL. 7
, pp. 313
-
-
Schiltmeyer, B.1
Cawello, W.2
Kropeit, D.3
-
28
-
-
33846243706
-
Low drug-interaction potential of lacosamide
-
Kropeit D, Koch B, Schiltmeyer B, et al. Low drug-interaction potential of lacosamide. J Pain 2005; 6(Suppl 1): S34
-
(2005)
J Pain
, vol.6
, Issue.SUPPL. 1
-
-
Kropeit, D.1
Koch, B.2
Schiltmeyer, B.3
-
29
-
-
77954907520
-
No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers
-
Cawello W, Nickel B, Eggert-Formella A. No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers. J Clin Pharmacol 2010; 50: 459-71
-
(2010)
J Clin Pharmacol
, vol.50
, pp. 459-471
-
-
Cawello, W.1
Nickel, B.2
Eggert-Formella, A.3
-
30
-
-
33846258011
-
Evaluation of the effect of oral lacosamide on concomitant AED plasma concentrations in patients with partial seizures
-
Jatuzis D, Biton V, Ben-Menachem, et al. Evaluation of the effect of oral lacosamide on concomitant AED plasma concentrations in patients with partial seizures. Epilepsia 2005; 46(Suppl 8): 170
-
(2005)
Epilepsia
, vol.46
, Issue.SUPPL. 8
, pp. 170
-
-
Jatuzis, D.1
Ben-Menachem, B.V.2
-
31
-
-
11144238504
-
SPM 927 does not interact with valproic acid and carbamazepine
-
Horstmann R, Bonn R, Cawello W, et al. SPM 927 does not interact with valproic acid and carbamazepine. Epilepsia 2003; 44(Suppl 9): 97
-
(2003)
Epilepsia
, vol.44
, Issue.SUPPL. 9
, pp. 97
-
-
Horstmann, R.1
Bonn, R.2
Cawello, W.3
-
32
-
-
77955173059
-
A high-performance liquid chromatography assay to monitor the new antiepileptic drug lacosamide in patients with epilepsy
-
Greenaway C, Ratnaraj N, Sander JW, et al. A high-performance liquid chromatography assay to monitor the new antiepileptic drug lacosamide in patients with epilepsy. Ther Drug Monit 2010; 32: 448-52
-
(2010)
Ther Drug Monit
, vol.32
, pp. 448-452
-
-
Greenaway, C.1
Ratnaraj, N.2
Sander, J.W.3
-
33
-
-
79951659549
-
Saliva and serum lacosamide concentrations in patients with epilepsy
-
Greenaway C, Ratnaraj N, Sander JW, et al. Saliva and serum lacosamide concentrations in patients with epilepsy. Epilepsia 2011; 52: 258-63
-
(2011)
Epilepsia
, vol.52
, pp. 258-263
-
-
Greenaway, C.1
Ratnaraj, N.2
Sander, J.W.3
-
34
-
-
77954896142
-
Therapeutic drug monitoring of the newer anti-epilepsy medications
-
Krasowski MD. Therapeutic drug monitoring of the newer anti-epilepsy medications. Pharmaceuticals (Basel) 2010; 3: 1909-35
-
(2010)
Pharmaceuticals (Basel)
, vol.3
, pp. 1909-1935
-
-
Krasowski, M.D.1
-
35
-
-
77955741352
-
Méthodologie pour l'évaluation du niveau de preuve du suivi thérapeutique pharmacologique
-
Le Guellec C, Simon N, Hulot JS, et al. Méthodologie pour l'évaluation du niveau de preuve du suivi thérapeutique pharmacologique. La Lettre du Pharmacologue 2009; 23: 21-5
-
(2009)
La Lettre du Pharmacologue
, vol.23
, pp. 21-25
-
-
Le Guellec, C.1
Simon, N.2
Hulot, J.S.3
|